Drug Trial Radar · NCT06114628
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,500
Planned (sponsor's estimate)
Start
Jan 9, 2024
Primary completion
Feb 24, 2027
Study completion Aug 11, 2027
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Radboud University Medical Center; London School of Hygiene and Tropical Medicine; University of Oxford; Research Center Borstel; Lygature; TASK Applied Science; Università Vita-Salute San Raffaele; Helmholtz Zentrum Munchen; KNCV Tuberculosis Foundation; Critical Path Institute; European Lung Foundation; Instituto de Saude Publica da Universidade do Porto; University of Liverpool; Institut de Recherche pour le Developpement; University of Hamburg-Eppendorf; University of California, San Francisco; TB Alliance; Find; University of Milan; University of St Andrews; Uppsala University; European Respiratory Society; Tuberculosis Network European Trialsgroup; Janssen, LP; Otsuka Pharmaceutical Development & Commercialization, Inc.; German Center for Infection Research; LMU Klinikum; University of Cambridge; GlaxoSmithKline
- First posted
- Nov 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB). The standard treatment for TB takes 24 weeks and uses four drugs. The consortium want to find new treatments that are faster but just as safe and effective. In the trial, two new drugs will be used, BTZ-043 and GSK3036656, along with the drugs that are already used to treat TB in a variety of combinations (11 different combinations initially). These new drugs have worked well in tests with animals and have reduced the amount of TB bacteria in people's sputum/phlegm when used alone for two weeks. These new drugs will be used in combination with other TB drugs for a longer time (up to 16 weeks) in people with TB. The UNITE4TB consortium want to see if they work well and are safe. This trial will take place at sites across the world and will involve people with TB of the lungs that would usually respond well to the standard treatment. But the new treatments being tested might also work for people with drug resistant TB, that's harder to treat. The trial has two parts. In the first part, different combinations of drugs will be tried on up to 700 people for 16 weeks. These combinations will be compared to the standard 24-week treatment to see which ones work the best and are safe. In the second part, the best combinations from the first part will be taken to try to find out what the best length of time is to give the treatment for. These combinations will be tried on up to 1800 people giving them either 8, 10, 12, 14 or 16 weeks treatment. The investigators will follow these people for a total of 72 weeks to make sure the treatment is working. The UNITE4TB consortium hope that this trial will find new treatments that are fast, safe, and effective for both regular TB and resistant TB. If it works, it can then be tested again in a bigger trial to be sure.
Conditions
- Pulmonary Tuberculosis
Interventions
GanfeboroleDrug
Oral daily dosage of 20mg.
BTZ-043Drug
Oral daily dosage of 1000mg.
Bedaquiline (B)Drug
Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Delamanid (D)Drug
Oral daily dosage of 300mg.
Pretomanid (Pa)Drug
Oral daily dosage of 200mg.
Moxifloxacin (M)Drug
Oral daily dosage of 400mg.
Linezolid (L)Drug
Oral daily dosage of 600mg for the first 8 weeks.
Pyrazinamide (Z)Drug
Oral daily dosage of 1200mg-2000mg depending on weight.
Rifampicin (R)Drug
Oral daily dosage of 450mg-750mg depending on weight.
Isoniazid (H)Drug
Oral daily dosage of 225mg-375mg depending on weight.
Ethambutol (E)Drug
Oral daily dosage of 825mg-1375mg depending on weight.
Delpazolid (DZD)Drug
Oral daily dosage of 1200mg
Quabodepistat (Q)Drug
Oral daily dosage of 30mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of change in log10(Time to Positivity of MGIT culture) (Phase 2B)Time frame: Over 0-12 weeks
- Favourable/Unfavourable outcome (Phase 2C)Time frame: at 48 weeks from randomisation
Locations
11 sites in 5 countries. Site status is shown where the registry gives one.
PMSI Institute of Pneumology "Chiril Draganiuc"
Chisinau, Moldova · Active not recruiting
TASK Brooklyn
Cape Town, South Africa · Recruiting
University of Cape Town Lung Institute
Cape Town, South Africa · Recruiting
TASK Eden
George, South Africa · Recruiting
NIMR Mbeya
Mbeya, Tanzania · Recruiting
Kibong'oto Infectious Diseases Hospital
Moshi, Tanzania · Recruiting
NIMR Mwanza
Mwanza, Tanzania · Recruiting
Joint Clinical Research Centre
Kampala, Uganda · Recruiting
Makerere University Lung Institute
Kampala, Uganda · Recruiting
National Lung Hospital
Hanoi, Vietnam · Active not recruiting
Pnth/Oucru
Ho Chi Minh City, Vietnam · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.